RESTRUCTURING AND OTHER SPECIAL CHARGES

9 Months Ended

Sep. 30, 2013

Restructuring and Related Activities [Abstract]

Restructuring and Other Special Charges

RESTRUCTURING AND OTHER SPECIAL CHARGES

During the first nine months of 2013, the Company recorded net restructuring charges of $17.8. The charges were comprised of $11.8 in severance and other personnel costs along with $8.8 in costs associated with facility closures and general integration initiatives. These charges were offset by the reversal of previously established reserves of $0.7 in unused severance and $2.1 in unused facility-related costs.

During the first nine months of 2012, the Company recorded net restructuring charges of $4.6. The charges were comprised of $11.4 related to severance and other personnel costs, and $2.5 primarily related to facility-related costs primarily related to ongoing integration activities of Orchid Cellmark Inc. ("Orchid") and the Integrated Genetics Division (formerly Genzyme Genetics*) and costs associated with the previously announced termination of an executive vice president. These charges were offset by the reversal of previously established reserves of $5.7 in unused severance and $3.6 in unused facility related costs.

As part of the Clearstone integration, the Company also recorded a $6.9 loss on the disposal of one its European subsidiaries in Other, net under Other income (expenses) during the nine months ended September 30, 2012.

* Genzyme Genetics and its logo are trademarks of Genzyme Corporation and used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are operated independently from Genzyme Corporation.